A Phase I Study to Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its Pharmacokinetic Profile in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Jun 2019
Price : $35 *
At a glance
- Drugs MG-S-2525 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Metagone Biotech
- 21 Jun 2019 Planned End Date changed from 1 Dec 2019 to 31 Dec 2021.
- 21 Jun 2019 Planned primary completion date changed from 1 Jun 2019 to 31 Dec 2021.
- 21 Jun 2019 Status changed from not yet recruiting to recruiting.